Related Experiment Video
Updated: May 8, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with
Marcel Grube1, Bianca Ribeiro de Souza2, Andrea Neilson2
1Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany; Department of Obstetrics and Gynecology, Diak Klinikum Landkreis Schwäbisch Hall, Schwäbisch Hall, Germany.
Objective:
Endometrioid ovarian carcinoma (ENOC) is increasingly recognized as a distinct disease entity, yet treatment still largely parallels high-grade serous disease management. We aimed to assemble a large, well-annotated ENOC cohort allowing us to study real-world treatment patterns with special interest on lymph node (LN) metastasis in presumed early-stage disease.
Methods:
ENOC cases from 22 centers across five countries underwent IHC-supported central pathology review. Standardized chart review captured patient characteristics, detailed surgical and adjuvant treatment data.
Results:
A total of 721 centrally confirmed ENOC cases diagnosed between 1984 and 2020 was assembled. Median age was 55.6 years; 86.0% presented with pelvic-confined disease, and 45.1% had grade 1 tumors. Complete resection was achieved in 96.5% of pT1/2 and 62.6% of pT3 cases. LN surgery (LNS) was performed in 58.3% of presumed early-stage cases, revealing nodal metastases in 2.6%, occurring in 4/255 (1.6%) after sampling and 5/95 (5.3%) after systematic LNS. No nodal metastases were observed in grade 1 pelvic-confined tumors (0/171). Adjuvant chemotherapy was administered in 68.0% of FIGOI/II cases and 95.5% of advanced-stage disease. Multivariable analyses revealed grade (p = 0.0006), stage (p = 0.0030) and chemotherapy (p = 0.0219) as independent prognosticators.
Conclusions:
This multinational initiative enabled detailed analyses in a large cohort of validated ENOC. According to our results, LNS may be safely omitted in patients with pelvic-confined G1 tumors, however, if LNS is deemed necessary, a systematic approach seems to result in higher detection rates. The findings presented herein may help to shape type-specific treatment, ultimately aiming to reduce not only ovarian carcinoma mortality but also treatment-associated morbidity.
